Veeva Systems Inc (VEEV) Stock Analysis
Verdict: HOLD
Veeva's high-margin SaaS monopoly in Life Sciences fuels resilient 18% growth and $1.39B FCF, but a P/E of 44.6x caps near-term valuation upside.
Investment score: 64/100
Analysis as of
Is Veeva Systems Inc stock worth reviewing? AI model thesis
Veeva's dominant software position in Life Sciences yields impressive profitability, but a 44.56x P/E ratio limits near-term multiple expansion.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 90/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Veeva Systems Inc opportunities and risks
What speaks for VEEV
- Expanding Vault platform adoption across R&D and Clinical operations
What speaks against VEEV
- Elevated valuation relative to peer group
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VEEV | 44.6x | 13.0x | 31.5x | 74.9% | 29.3% | 3.7% |
| DOCS | 30.0x | 7.6x | 19.4x | 88.1% | 25.5% | 6.0% |
| HTFL | n/a | 19.4x | n/a | 80.1% | -55.8% | -1.4% |
| WAY | 36.4x | 4.2x | 15.0x | 69.1% | 11.2% | 4.9% |
| SDGR | n/a | 5.7x | n/a | 56.9% | -21.0% | -2.2% |
| CERT | n/a | 3.2x | 16.9x | 58.3% | -16.7% | 4.7% |
| Peer median | n/a | 5.7x | 15.0x | 69.1% | -16.7% | 4.7% |
Frequently asked questions about Veeva Systems Inc (VEEV)
Is VEEV stock a good investment?
The cached TradeMates AI model rates Veeva Systems Inc as HOLD with an investment score of 64/100. Veeva's dominant software position in Life Sciences yields impressive profitability, but a 44.56x P/E ratio limits near-term multiple expansion. This is algorithmic model output, not personal investment advice.
Is VEEV stock a buy?
The TradeMates model verdict for VEEV is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.